Cue Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
13/05/2025 19:41
Cue Biopharma Inc CUE.OQ reported a quarterly adjusted loss of 17 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of three analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -18 cents to -13 cents per share. Revenue fell 75.5% to $421.00 thousand from a year ago; analysts expected $1.27 million. Cue Biopharma Inc's reported EPS for the quarter was a loss of 17 cents. The company reported a quarterly loss of $12.26 million. Cue Biopharma Inc shares had fallen by 17.6% this quarter and lost 31.1% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 2.1% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for Cue Biopharma Inc is $3.00 This summary was machine generated from LSEG data May 13 at 06:41 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.15 | -0.17 | Missed |
| Dec. 31 2024 | -0.16 | -0.13 | Beat |
| Sep. 30 2024 | -0.19 | -0.17 | Beat |
| Jun. 30 2024 | -0.28 | -0.20 | Beat |